Identification of Protein Kinases Required for NF2 Signaling
Annual rept. 1 Dec 2005-30 Dec 2006
INSTITUTE FOR CANCER RESEARCH PHILADELPHIA PA
Pagination or Media Count:
The purpose of this concept award grant is to uncover potential drug targets for treatment of Neurofibromatosis type 2 NF2. We planned a synthetic lethal screen, using RNAi technology to uncover protein kinases and phosphatases that are specifically required for the survival of NF2-null cells. We obtained and reformatted a murine siRNA library against all known protein kinases and phosphatases. We also obtained NF2floxflox mouse embryo fibroblasts and used Ore recombinase to convert these to a NF24- genotype. We then tested a large number of transfection procedures to determine the most effective and least toxic method for delivery of siRNA into these cells, and optimized this procedure for a high throughput assay. Having carefully established the conditions for the screen, we are carrying out the main, most important experiment the large scale screen for synthetic lethality.
- Anatomy and Physiology
- Medicine and Medical Research